Harbin Medisan Pharmaceutical Co., Ltd.
Symbool: 002900.SZ
SHZ
10.31
CNYMarktprijs vandaag
62.4601
Koers/Winst Verhouding
1.8348
Koers/Winst Groei Verhouding
3.19B
MRK Kapitalisatie
- 0.01%
DIV Rendement
Harbin Medisan Pharmaceutical Co., Ltd. (002900-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1048.9 | 1293.9 | 1111.5 | ||||||||||||
balance-sheet.row.short-term-investments | 0 | 57.8 | 91.3 | 581.7 | ||||||||||||
balance-sheet.row.net-receivables | 0 | 150.6 | 164.1 | 149.6 | ||||||||||||
balance-sheet.row.inventory | 0 | 208.8 | 161.2 | 156.5 | ||||||||||||
balance-sheet.row.other-current-assets | 0 | 28.2 | 4.5 | 9.5 | ||||||||||||
balance-sheet.row.total-current-assets | 0 | 1436.4 | 1623.7 | 1427.2 | ||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 1081.6 | 882.4 | 925.3 | ||||||||||||
balance-sheet.row.goodwill | 0 | 1.3 | 0.5 | 9.4 | ||||||||||||
balance-sheet.row.intangible-assets | 0 | 141.2 | 71.7 | 62.5 | ||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 142.5 | 72.2 | 71.9 | ||||||||||||
balance-sheet.row.long-term-investments | 0 | 651.2 | 555.6 | 22.8 | ||||||||||||
balance-sheet.row.tax-assets | 0 | 23.1 | 23.8 | 25.8 | ||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 108.1 | 119.1 | 592.4 | ||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 2006.5 | 1653.1 | 1638.3 | ||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.total-assets | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.account-payables | 0 | 182.1 | 120.8 | 105.2 | ||||||||||||
balance-sheet.row.short-term-debt | 0 | 480.2 | 233.8 | 274.8 | ||||||||||||
balance-sheet.row.tax-payables | 0 | 3.1 | 12.2 | 11.2 | ||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 238.2 | 422.9 | 212.9 | ||||||||||||
Deferred Revenue Non Current | 0 | 79 | 83.9 | 89 | ||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||
balance-sheet.row.other-current-liab | 0 | 7.9 | 188.3 | 2.5 | ||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 449.7 | 627.1 | 412.4 | ||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 8.3 | 5.1 | 8 | ||||||||||||
balance-sheet.row.total-liab | 0 | 1294.8 | 1224.8 | 949 | ||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||
balance-sheet.row.common-stock | 0 | 316.4 | 316.6 | 316.6 | ||||||||||||
balance-sheet.row.retained-earnings | 0 | 612.9 | 570.7 | 639.6 | ||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 162.5 | 192.3 | ||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1211.2 | 990.9 | 952.9 | ||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2140.5 | 2040.7 | 2101.4 | ||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 3443 | 3276.8 | 3065.5 | ||||||||||||
balance-sheet.row.minority-interest | 0 | 7.7 | 11.3 | 15 | ||||||||||||
balance-sheet.row.total-equity | 0 | 2148.2 | 2052 | 2116.5 | ||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||
Total Investments | 0 | 709 | 646.9 | 604.5 | ||||||||||||
balance-sheet.row.total-debt | 0 | 718.4 | 656.7 | 487.7 | ||||||||||||
balance-sheet.row.net-debt | 0 | -272.8 | -545.9 | -42.2 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 26.5 | 349.7 | 26.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 106.6 | 99.1 | 79.9 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.stock-based-compensation | 0 | -11.7 | -95 | 1.4 | |||||||||||
cash-flows.row.change-in-working-capital | 0 | 49.5 | 107.4 | -160.1 | |||||||||||
cash-flows.row.account-receivables | 0 | -10 | 49.6 | 49.1 | |||||||||||
cash-flows.row.inventory | 0 | 0.6 | 26.5 | 31.9 | |||||||||||
cash-flows.row.account-payables | 0 | 47.2 | -63.7 | -239.6 | |||||||||||
cash-flows.row.other-working-capital | 0 | 11.7 | 95 | -1.4 | |||||||||||
cash-flows.row.other-non-cash-items | 0 | -37.9 | -568.8 | 49 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0.3 | 11.6 | 146.4 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | -72 | -1113.7 | -1091 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 580.2 | 901.9 | 1437.6 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -4.1 | -145.9 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 419.3 | -278.2 | 201.3 | |||||||||||
cash-flows.row.debt-repayment | 0 | -270.2 | -269.5 | -230 | |||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | -109.3 | -34.3 | -95.8 | |||||||||||
cash-flows.row.other-financing-activites | 0 | 272.4 | 260.1 | 323.2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -107.1 | -43.7 | -2.6 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | 0 | 456.8 | -334.5 | 194.2 | |||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 782.3 | 325.5 | 660 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 325.5 | 660 | 465.7 | |||||||||||
cash-flows.row.operating-cash-flow | 0 | 144.6 | -12.5 | -4.5 | |||||||||||
cash-flows.row.capital-expenditure | 0 | -89.2 | -73.9 | -145.9 | |||||||||||
cash-flows.row.free-cash-flow | 0 | 55.4 | -86.5 | -150.4 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1186.8 | 1028.4 | 945.8 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 476.4 | 365.6 | 309.4 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 710.4 | 662.8 | 636.4 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 693.4 | 679.6 | 765.2 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 1169.7 | 1045.1 | 1074.6 | ||||||||||||
income-statement-row.row.interest-income | 0 | 27.9 | 28.3 | 11.8 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 2.4 | 110.5 | 46.5 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 2.4 | -17.5 | -1.9 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 22.9 | 22.6 | 13.8 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 108.7 | 106.6 | 122.9 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | 79 | 57.6 | 454.8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | 81.4 | 40.1 | 452.9 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 11.3 | 13.6 | 103.2 | ||||||||||||
income-statement-row.row.net-income | 0 | 73.7 | 30.2 | 351 |
Vaak gestelde vragen
Wat is Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) totale activa?
Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) totale activa is 3442984089.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.582.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.049.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.026.
Wat is Harbin Medisan Pharmaceutical Co., Ltd. (002900.SZ) nettowinst (netto-inkomen)?
De nettowinst is 73663110.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 718376453.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 693357200.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.